Predictive impact of polymorphism of PNPLA3 on HCC development after interferon therapy in Japanese patients with chronic hepatitis C

SpringerPlus

Table 4 Stepwise logistic regression analysis of the factors related to PNPLA3 148 M

	Univariate analysis		Multivariate analysis
Factors	Odds ratio (range^†)	p	Odds ratio (range^†)	p
Age (years)	0.98 (0.95-1.0)	0.12
Sex (1: male)	0.69 (0.41-1.2)	0.17
Body mass index	1.0 (0.93-1.1)	0.73
Liver fibrosis	0.68 (0.48-0.96)	0.028	0.78 (0.54-1.1)	0.20
Hepatitis activity	1.3 (0.70-2.3)	0.43
Liver steatosis (1: >30%)	0.96 (0.55-1.7)	0.87
Amino acid 70 of HCV core (1: glutamine)	0.80 (0.38-1.7)	0.56
Alanine aminotransferase (1: >40 IU/L)	0.72 (0.51-1.0)	0.068
Platelet count (1: >1.5x10⁵/mm³)	2.1 (0.93-4.7)	0.076
Alpha fetoprotein (1: >5 ng/mL)	0.36 (0.20-0.65)	0.0007	0.42 (0.21-0.85)	0.017
HOMA-IR	0.18 (0.92-1.0)	0.18

^†: 95% confidence interval; PNPLA3, patatin-like phospholipase domain-containing protein 3; HOMA-IR, homeostasis model assessment insulin resistance.